Trials / Not Yet Recruiting
Not Yet RecruitingNCT06441084
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation
A Phase I or II Clinical Trial Evaluating the Safety and Efficacy of NCR300 Injection in Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Nuwacell Biotechnologies Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.
Detailed description
This is an open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability and preliminary efficacy of NCR300 injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NCR300 injection | Subjects will receive at least 1 cycle of NCR300 injection. |
Timeline
- Start date
- 2024-06-30
- Primary completion
- 2028-12-31
- Completion
- 2031-12-31
- First posted
- 2024-06-04
- Last updated
- 2024-06-04
Source: ClinicalTrials.gov record NCT06441084. Inclusion in this directory is not an endorsement.